(9ci)-4,5,6,7-四氢-1H-苯并咪唑-5-羰酰氯

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (9ci)-4,5,6,7-四氢-1H-苯并咪唑-5-羰酰氯
• 英文名称: 4,5,6,7-tetrahydrobenzimidazole-5-carboxylic acid hydro-chloride
• 英文别名: 4,5,6,7-tetrahydro-1H-benzimidazole-5-carbonyl chloride
• 化学式: C₈H₉ClN₂O
• 分子量: 184.625
• InChiKey: WNLAYQWXHRLHHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4,5,6,7-四氢-1H-苯并[d]咪唑-6-羧酸乙酯 以 盐酸 、 丙酮 为溶剂， 生成 (9ci)-4,5,6,7-四氢-1H-苯并咪唑-5-羰酰氯
  参考文献：
  名称：

  Indoline compound and 5-HT.sub.3 receptor antagonist containing the same

  摘要：

  本发明涉及一种由一般式表示的吲哚啉化合物：##STR1##其中R.sup.1代表基团##STR2##R.sup.2代表可能被取代的苯基或芳香族杂环基团，R.sup.3代表氢、卤素或较低的烷基、羟基、较低的烷氧基、氨基甲酰基或较低的烷氧羰基基团，以及其生理上可接受的盐和溶剂化物，以及含有它们作为有效成分的5-HT.sub.3受体拮抗剂。本发明的吲哚啉化合物对肠道5-HT.sub.3受体具有比已知的5-HT.sub.3受体拮抗剂更强的拮抗作用，并且具有出色的持续作用，因此它们可用作预防或治疗化疗或放射治疗引起的呕吐或刺激性、肠易激综合征、腹泻等的药物。

  公开号：

  US05677326A1

文献信息

• Novel Process for Producing Ramosetron or Its Salt
  申请人：Inakoshi Masatoshi

  公开号：US20090069570A1

  公开（公告）日：2009-03-12

  [Problems] To provide a novel process for producing ramosetron or its salt that is useful as a pharmaceutical, especially as a therapeutic and/or preventive agent for digestive symptoms caused by administration of an anti-malignant tumor agent, diarrheal-type irritable bowel syndrome, diarrheal symptoms of irritable bowel syndrome, etc. [Means for Resolution] Ramosetron or its salt can be produced by reacting a compound of the formula (I): [wherein X is a halogen] or a salt thereof with 1-methyl-1H-indole in the presence of a Lewis acid selected from the group consisting of a lower alkylaluminum dihalide, a di-lower alkylaluminum halide, a tri-lower alkylaluminum and a lower alkylaluminum sesquihalide.

  [问题] 提供一种新的生产拉莫色隆或其盐的方法，该方法可作为制药用途，特别是作为治疗和/或预防由抗恶性肿瘤药物引起的消化症状，腹泻型肠易激综合症，肠易激综合症腹泻症状等的治疗和/或预防剂。 [解决方法] 在低级烷基铝二卤化物，低级烷基铝卤化物，三低级烷基铝和低级烷基铝半卤化物的Lewis酸存在下，将公式（I）化合物[其中X为卤素]或其盐与1-甲基-1H-吲哚反应，即可制备拉莫色隆或其盐。
• NOVEL PROCESS FOR PRODUCING RAMOSETRON OR ITS SALT
  申请人：Astellas Pharma Inc.

  公开号：EP1870408A1

  公开（公告）日：2007-12-26

  [Problems] To provide a novel process for producing ramosetron or its salt that is useful as a pharmaceutical, especially as a therapeutic and/or preventive agent for digestive symptoms caused by administration of an anti-malignant tumor agent, diarrheal-type irritable bowel syndrome, diarrheal symptoms of irritable bowel syndrome, etc. [Means for Resolution] Ramosetron or its salt can be produced by reacting a compound of the formula (I): [wherein X is a halogen] or a salt thereof with 1-methyl-1H-indole in the presence of a Lewis acid selected from the group consisting of a lower alkylaluminum dihalide, a di-lower alkylaluminum halide, a tri-lower alkylaluminum and a lower alkylaluminum sesquihalide.

  [问题] 提供一种生产雷莫司琼或其盐的新工艺，该工艺可用作药物，特别是用作治疗和/或 预防因服用抗恶性肿瘤药物引起的消化道症状、腹泻型肠易激综合征、肠易激综合征的腹泻 症状等的药物。 [解决方法] 雷莫司琼或其盐可以通过式（I）化合物反应制得： [其中 X 为卤素]或其盐与 1-甲基-1H-吲哚在选自低烷基铝二卤化物、二低烷基铝卤化物、三低烷基铝和低烷基铝倍半卤化物组成的路易斯酸组中的存在下反应。
• US7652052B2
  申请人：——

  公开号：US7652052B2

  公开（公告）日：2010-01-26
• Indoline compound and 5-HT.sub.3 receptor antagonist containing the same
  申请人：Tokyo Tanabe Company Limited

  公开号：US05677326A1

  公开（公告）日：1997-10-14

  Indoline compounds represented by the general formula: ##STR1## wherein R.sup.1 represents the group ##STR2## R.sup.2 represents a phenyl group which may be substituted or an aromatic heterocyclic group, and R.sup.3 represents hydrogen, a halogen, or a lower alkyl group, hydroxyl group, lower alkoxy group, carbamoyl group or lower alkoxycarbonyl group, and physiologically acceptable salts thereof, and their solvates, as well as 5-HT.sub.3 receptor antagonists containing them as effective components. The indoline compounds of the invention have stronger antagonism against intestinal 5-HT.sub.3 receptors than known 5-HT.sub.3 receptor antagonists and also have excellent sustained action, making them useful as prophylactic or therapeutic agents against vomiting or irritancy induced by chemotherapy or radiation, irritable bowel syndrome, diarrhea, and the like.

  本发明涉及一种由一般式表示的吲哚啉化合物：##STR1##其中R.sup.1代表基团##STR2##R.sup.2代表可能被取代的苯基或芳香族杂环基团，R.sup.3代表氢、卤素或较低的烷基、羟基、较低的烷氧基、氨基甲酰基或较低的烷氧羰基基团，以及其生理上可接受的盐和溶剂化物，以及含有它们作为有效成分的5-HT.sub.3受体拮抗剂。本发明的吲哚啉化合物对肠道5-HT.sub.3受体具有比已知的5-HT.sub.3受体拮抗剂更强的拮抗作用，并且具有出色的持续作用，因此它们可用作预防或治疗化疗或放射治疗引起的呕吐或刺激性、肠易激综合征、腹泻等的药物。